The analysis highlights that Vertex Pharmaceuticals, with its dominant cystic fibrosis franchise and expansion into new disease areas like sickle cell disease, is growing faster and boasts superior operating margins. In FY 2025, Vertex's revenue reached nearly $12.1 billion, with a net margin of approximately 32.7% and a conservative debt-to-equity ratio of 0.2x. Amgen, while a dependable, dividend-paying biotech with diverse brands, reported FY 2025 revenue of nearly $36.7 billion, a net margin of approximately 21%, and a debt-to-equity ratio of 6.3x. Vertex's strong financial position and ambitious R&D pipeline make it a more compelling long-term opportunity for investors.